Tempest Therapeutics, Inc.·4

Jan 6, 5:00 PM ET

Maestas Nicholas 4

4 · Tempest Therapeutics, Inc. · Filed Jan 6, 2025

Insider Transaction Report

Form 4
Period: 2025-01-02
Maestas Nicholas
Chief Financial Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2025-01-02+200,000200,000 total
    Exercise: $0.86Exp: 2035-01-01Common Stock (200,000 underlying)
Footnotes (1)
  • [F1]These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

Documents

1 file
  • 4
    form4-01062025_050112.xmlPrimary